Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2019-06-17 Regulatory Filings
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is titled as an announcement regarding reimbursement coverage in France for a specific medical procedure (Confocal Laser Endomicroscopy for Barrett's Esophagus). It details a decision made by the French National Association of Health Insurance Funds (UNCAM) and published in the Official Journal, setting specific tariffs. This type of announcement, which communicates a specific operational or regulatory update concerning pricing, coverage, or procedure codes, is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to financial performance highlights. However, since it is a specific announcement about a regulatory/reimbursement decision rather than a comprehensive financial report (10-K, IR) or a standard earnings release (ER), and it doesn't fit the other specific categories (like M&A, Dividend, Management Change), the most appropriate general category for a specific, non-standard regulatory update is RNS. Given the content is a press release announcing a specific regulatory/reimbursement event, it is not a full report, thus RNS is the best fit among the options, acting as a specific regulatory announcement.
2019-06-17 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 98% confidence The document is a press release titled "Mauna Kea Technologies annonce la souscription d'une tranche de 5 M€ auprès de IPF Partners" (Mauna Kea Technologies announces the subscription of a €5M tranche from IPF Partners). It details a specific financing activity: the subscription of a debt tranche under an existing agreement. This directly relates to fundraising, financing activities, and capital structure changes. Based on the definitions, this aligns perfectly with the 'Capital/Financing Update' category (CAP). The document is short and is an announcement, not a comprehensive report like a 10-K or IR.
2019-05-29 French
Inside Information / Other news releases
Capital/Financing Update Classification · 98% confidence The document is a press release dated May 29, 2019, announcing the exercise of a €5 million debt tranche with IPF Partners, referencing an amendment to a Debt Subscription Agreement. This action directly relates to the company's financing activities and capital structure adjustments (specifically debt conversion/utilization). This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific financing event.
2019-05-29 English
Modalités de mise à disposition des documents préparatoires à l'AG
AGM Information Classification · 98% confidence The document title explicitly mentions 'Modalités de mise à disposition des documents préparatoires à l'Assemblée Générale Mixte du 20 juin 2019' (Procedures for making available the preparatory documents for the Combined General Meeting of June 20, 2019). This clearly indicates the document is an announcement related to the upcoming Annual General Meeting (AGM). Since the document itself is short and serves to inform shareholders where to find the preparatory materials (on the website or upon request), it fits the description of an AGM-related announcement, specifically aligning best with the 'AGM Information' category (AGM-R), which covers presentations and materials shared during the AGM, or potentially a precursor announcement. Given the focus on the AGM date and document availability, AGM-R is the most appropriate classification.
2019-05-29 French
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 95% confidence The document is a press release from Mauna Kea Technologies announcing its participation and the presentation of 17 studies related to its Cellvizio product at the Digestive Disease Week® (DDW) 2019 conference. It details the titles, dates, and presenters of key scientific presentations and posters. This type of announcement, detailing scientific findings or participation in an industry event, is typically classified as an Investor Presentation (IP) if it were the actual presentation slides, or an Earnings Release (ER) if it summarized financial results. Since this document is an announcement about scientific data being presented at a medical conference, and it is not a formal regulatory filing (like 10-K or IR), nor a management discussion (MDA), nor a general regulatory filing (RNS), the closest fit among the provided options that covers company activities and investor-relevant information outside of core financial reporting is Investor Presentation (IP), as it details the content that will be presented to investors/the medical community. However, given the structure, it reads most like a general corporate update or press release highlighting scientific progress, which often falls under Investor Presentation (IP) when focusing on product value and clinical data, or sometimes RNS if it were a less specific update. Since it is a detailed announcement of scientific data being shared, IP is the most appropriate category for investor-facing material detailing clinical value.
2019-05-16 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release from Mauna Kea Technologies announcing the presentation of 17 abstracts related to their Cellvizio® platform at the Digestive Disease Week® (DDW) Conference. This is a corporate announcement detailing scientific/clinical updates and participation in an industry event, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). It is an announcement about company activities and scientific progress aimed at investors and the medical community. Since it is not a standard regulatory filing, nor a specific report type like a dividend notice or management discussion, it fits best under the general category for corporate news or investor relations material. Given the options, 'Investor Presentation' (IP) is close as it relates to investor communication, but this is specifically an announcement about external conference presentations. 'Regulatory Filings' (RNS) is the best fallback for general corporate news that doesn't fit the highly specific categories, although 'Investor Presentation' (IP) might also be considered if the content were structured as a deck. However, since it is a press release detailing external scientific presentations, it is most accurately classified as a general corporate announcement, which often falls under RNS if a more specific category like 'IP' (which usually implies the company's own presentation deck) is not a perfect fit. Given the context of sharing scientific/clinical data updates, 'Investor Presentation' (IP) is a strong candidate as these announcements often accompany or precede investor briefings. However, since the core content is an announcement of external conference participation, and not the presentation material itself, RNS (Regulatory Filings/General Announcement) is the safest general classification for non-standard corporate news releases.
2019-05-16 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.